Arizona State Retirement System grew its holdings in Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 42.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 15,446 shares of the technology company’s stock after acquiring an additional 4,640 shares during the period. Arizona State Retirement System’s holdings in Cogent Biosciences were worth $151,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in COGT. Federated Hermes Inc. purchased a new position in shares of Cogent Biosciences in the 3rd quarter valued at $46,000. Quantbot Technologies LP raised its stake in shares of Cogent Biosciences by 150.0% in the 2nd quarter. Quantbot Technologies LP now owns 6,000 shares of the technology company’s stock valued at $54,000 after acquiring an additional 3,600 shares during the period. Royal Bank of Canada raised its stake in shares of Cogent Biosciences by 56.3% in the 2nd quarter. Royal Bank of Canada now owns 5,630 shares of the technology company’s stock valued at $66,000 after acquiring an additional 2,027 shares during the period. Russell Investments Group Ltd. purchased a new position in shares of Cogent Biosciences in the 1st quarter valued at $72,000. Finally, Renaissance Technologies LLC purchased a new stake in Cogent Biosciences during the 1st quarter worth $86,000.
Cogent Biosciences Stock Performance
NASDAQ COGT opened at $5.88 on Friday. Cogent Biosciences, Inc. has a one year low of $3.67 and a one year high of $14.50. The company has a 50-day simple moving average of $5.50 and a 200-day simple moving average of $8.48. The firm has a market capitalization of $506.39 million, a PE ratio of -2.52 and a beta of 1.39.
Analyst Ratings Changes
Cogent Biosciences Company Profile
Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target exon 17 mutations found within the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
- Five stocks we like better than Cogent Biosciences
- Pros And Cons Of Monthly Dividend Stocks
- MarketBeat Week in Review – 2/5 – 2/9
- Airline Stocks – Top Airline Stocks to Buy Now
- Cloudflare results spark analysts reset: 25% upside ahead
- What is a Stock Market Index and How Do You Use Them?
- Beyond Nvidia: The hidden stars with 200% earnings growth
Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.